SABS
SAB Biotherapeutics (SABS)
$61
About SAB Biotherapeutics (SABS)
SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company. It is engaged in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. The firm produces human polyclonal immunotherapies and its versatile DiversitAb platform is applicable for unmet needs in human diseases. SAB Biotherapeutics was founded by Eddie J. Sullivan and Christine E. Hamilton in July 2014 and is headquartered in Miami Beach, FL.
Details
Daily high
$1.70
Daily low
$1.58
Price at open
$1.61
52 Week High
$5.89
52 Week Low
$1.45
Market cap
14.9M
Dividend yield
0.00%
Volume
87,385
Avg. volume
74,620
P/E ratio
-.26
SAB Biotherapeutics News
Details
Daily high
$1.70
Daily low
$1.58
Price at open
$1.61
52 Week High
$5.89
52 Week Low
$1.45
Market cap
14.9M
Dividend yield
0.00%
Volume
87,385
Avg. volume
74,620
P/E ratio
-.26